Regeneron’s bispecific lymphoma antibody odronextamab wins FDA priority review
The FDA has set 31 March 2024 as the PDUFA action date for reviewing odronextamab as third-line therapy for FL and DLBCL.
The FDA has set 31 March 2024 as the PDUFA action date for reviewing odronextamab as third-line therapy for FL and DLBCL.
What's Your Reaction?
